The Gross Margin of Kiniksa Pharmaceuticals International, PLC (KNSA) is
88.54%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-12-31 |
88.54%
|
| 2024-12-31 |
85.61%
|
| 2023-12-31 |
87.64%
|
| 2022-12-31 |
89.60%
|
| 2021-12-31 |
76.39%
|
| 2020-12-31 |
76.39%
|
| Ticker |
Name |
Value |
|
PASG
|
Passage Bio Inc
|
7775.20%
|
|
AKRO
|
Akero Therapeutics Inc
|
7775.20%
|
|
ATRA
|
Atara Biotherapeutics, Inc.
|
82.44%
|
|
CYDY
|
Cytodyn Inc
|
-27547.74%
|
|
PCVX
|
Vaxcyte, Inc.
|
7775.20%
|
|
ITOS
|
iTeos Therapeutics Inc
|
7775.20%
|
|
NWBO
|
Northwest Biotherapeutics Inc
|
100.00%
|
|
PRAX
|
Praxis Precision Medicines, Inc.
|
7775.20%
|
|
ALGS
|
Aligos Therapeutics, Inc.
|
7775.20%
|
|
ANNX
|
Annexon, Inc.
|
7775.20%
|
|
BTAI
|
BioXcel Therapeutics Inc
|
74.45%
|
|
RYTM
|
Rhythm Pharmaceuticals, Inc.
|
89.73%
|
|
ADVM
|
Adverum Biotechnologies Inc
|
7775.20%
|
|
ORIC
|
ORIC Pharmaceuticals, Inc.
|
7775.20%
|
|
AFMD
|
Affimed NV
|
83.70%
|
|
ARCT
|
Arcturus Therapeutics Holdings Inc
|
7775.20%
|
|
AVXL
|
Anavex Life Sciences Corp
|
7775.20%
|
|
TSHA
|
Taysha Gene Therapies, Inc.
|
7775.20%
|
|
EPIX
|
ESSA Pharma Inc
|
7775.20%
|
|
FDMT
|
4D Molecular Therapeutics Inc
|
7775.20%
|
|
MRSN
|
Mersana Therapeutics Inc
|
7775.20%
|
|
PRTA
|
Prothena Corporation PLC
|
7775.20%
|
|
SNDX
|
Syndax Pharmaceuticals, Inc.
|
95.96%
|
|
CMPS
|
Compass Pathways PLC
|
7775.20%
|
|
DVAX
|
Dynavax Technologies Corp
|
82.17%
|
|
KROS
|
Keros Therapeutics, Inc.
|
7775.20%
|